Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 1999, p. 2077-2080, Vol. 43, No. 8
Eccles Institute of Human Genetics,
University of Utah, Salt Lake City, Utah 841121;
Georgia VA Research Center for AIDS and HIV
Infections2 and Department of
Pediatrics, Emory University School of
Medicine,3 Decatur, Georgia 30033; and
Center for Comparative Medicine, University of California,
Davis, California 956164
Received 18 November 1998/Returned for modification 8 March
1999/Accepted 13 May 1999
A P157S mutation in the reverse transcriptase (RT) of human
immunodeficiency virus type 1 conferred fivefold resistance to (
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
A New Point Mutation (P157S) in the Reverse
Transcriptase of Human Immunodeficiency Virus Type 1 Confers Low-Level
Resistance to (
)-
-2',3'-Dideoxy-3'-Thiacytidine
)-
-2',3'-dideoxy-3'-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3'-azido-3'-deoxythymidine (AZT) and to
(R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). A similar
increase in susceptibility to AZT and to PMPA was also conferred by the
M184V mutation in RT.
*
Corresponding author. Mailing address: Eccles Institute
of Human Genetics, University of Utah, Salt Lake City, UT 84112. Phone: (801) 585-6342. Fax: (801) 585-3501. E-mail:
bpreston{at}hci.utah.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»